A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in ApcΔ14/+ mice by Nakanishi, M et al.
This is a repository copy of A novel bioactive derivative of eicosapentaenoic acid (EPA) 
suppresses intestinal tumor development in ApcΔ14/+ mice.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/131940/
Version: Accepted Version
Article:
Nakanishi, M, Hanley, MP, Zha, R et al. (6 more authors) (2018) A novel bioactive 
derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in 
ApcΔ14/+ mice. Carcinogenesis, 39 (3). pp. 429-438. ISSN 0143-3334 
https://doi.org/10.1093/carcin/bgx136
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Ac
ce
pte
d M
an
us
cri
pt
 
© The Author(s) 2017. Published by Oxford University Press. All rights reserved. For 
Permissions, please email: journals.permissions@oup.com. 
A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal 
tumor development in Apcǻ+ mice 
 
Masako Nakanishi1, Matthew P. Hanley1,3, Ruochen Zha1,2, Yuichi Igarashi1, Mark A. 
Hull4, Gary Mathias3, Frank Sciavolino3, James J. Grady1,2 and Daniel W. Rosenberg1 
 
1
 University of Connecticut Health, Farmington, CT 
2
 Connecticut Institute for Clinical and Translational Science, Farmington, CT 
3
 Thetis Pharmaceuticals, Branford, CT 
4
 Leeds Institute of Biomedical & Clinical Sciences, University of Leeds, Leeds, UK 
Running title: EPA treatment suppresses intestinal tumorigenesis  
 
Keywords: Familial adenomatous polyposis, colon cancer, EPA, cancer prevention, 
omega-3 PUFA 
Financial support: Thetis Pharmaceuticals 
Disclosure of Potential Conflicts of Interest: M. Hanley, G. Mathias and F. Sciavolino 
are employees of Thetis Pharmaceuticals. No potential conflicts of interest were 
disclosed by the other authors. 
 
Corresponding author:  
Daniel W. Rosenb rg, Ph.D. 
University of Connecticut Health  
Center for Molecular Medicine 
263 Farmington Ave. 
Farmington, CT 06030-3101 
Phone: 860-679-8794 
Fax: 860-679-7639 
e-mail: Rosenberg@uchc.edu 
Downloaded from https://academic.oup.com/carcin/advance-article-abstract/doi/10.1093/carcin/bgx136/4675322
by NERL, Daniel Rosenberg
on 07 December 2017
Ac
ce
pte
d M
an
us
cri
pt
 
 2 
 
Summary:  
  
A novel ionic derivative of EPA significantly suppresses intestinal tumor 
development in Apcǻ mice, and the regression tree analyses to the global lipidomic 
data provide new insights into specific eicosanoid metabolites and their potential to exert 
control over early neoplasia.  
 
Abstract 
 
 Familial adenomatous polyposis (FAP) is a genetic disorder characterized by the 
development of hundreds of polyps throughout the colon.  Without prophylactic 
colectomy, most individuals with FAP develop colorectal cancer at an early age. 
Treatment with eicosapentaenoic acid (EPA) in the free fatty acid form (EPA-FFA) has 
been shown to reduce polyp burden in FAP patients.  Since high-purity EPA-FFA is 
subject to rapid oxidation, a stable form of EPA compound has been developed in the 
form of magnesium l-lysinate bis-eicosapentaenoate (TP-252).  We assessed the 
chemopreventive efficacy of TP-252 on intestinal tumor formation using Apcǻ+ mice, 
and compared it to EPA-FFA.  TP-252 was supplemented in a modified AIN-93G diet at 
1, 2, or 4% and EPA-FFA at 2.5% by weight, and administered to mice for 11 weeks.  
We found that administration of TP-252 significantly reduced tumor number and size in 
the small intestine and colon in a dose-related manner and as effectively as EPA-FFA.  
To gain further insight into the cancer protection afforded to the colon, we performed a 
comprehensive lipidomic analysis of total fatty acid composition and eicosanoid 
metabolites.   Treatment with TP-252 significantly decreased the levels of arachidonic 
acid (AA) and increased EPA concentrations within the colonic mucosa.  Furthermore, a 
classification and regression tree (CART) analysis revealed that a subset of fatty acids, 
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 3 
including EPA and DHA, and their downstream metabolites, including PGE3 and 14-
HDoHE, were strongly associated with anti-neoplastic activity.  These results indicate 
that TP-252 warrants further clinical development as a potential strategy for delaying 
colectomy in adolescent FAP patients. 
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Introduction 
 
Familial Adenomatous Polyposis (FAP) is a rare genetic disease characterized 
by the formation of numerous colonic polyps occurring at an early age (1).  FAP patients 
carry a germ-line mutation in the Adenomatous Polyposis Coli (APC) tumor suppressor 
gene.  Upon loss of heterozygosity (LoH) of the wild-type allele (1), colon tumors 
develop rapidly throughout the colon.  Screening, surveillance and prophylactic 
colectomy constitute the current standard of care for the management of FAP (2).  
Although a number of clinical and animal studies have demonstrated the limited 
chemopreventive efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) for the 
management of cancer risk in FAP patients (3-5), there are no FDA-approved drugs for 
the treatment of this disease.  Given the significant likelihood of advanced neoplasia and 
the clinical consequences of colectomy in young FAP patients, the development of 
therapies to control colorectal polyp burden is strongly justified.    
 
7KHUH LV HYLGHQFH IURP ERWK FOLQLFDO DQG DQLPDO VWXGLHV WKDW RPHJD Ȧ-3 
polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA), suppress 
intestinal polyp formation (6-8).  Fini et al. (9) showed that a diet containing the free fatty 
acid form of EPA (EPA-FFA) reduced polyp burden in the ApcMin/+ mouse model of FAP.  
Moreover, treatment of FAP patients for six months with EPA-FFA showed a 22% and 
30% net reduction in adenomatous polyp number and size, respectively, in a 
randomized, double-blinded, placebo-controlled trial (7). 
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 5 
The underlying basis for the tumor suppressive activity of EPA has been 
attributed, in part, to its ability to act as a competitive inhibitor of AA oxygenation (10).  
Intake of EPA-FFA significantly increases the intestinal mucosal content of EPA, 
effectively displacing AA within membrane phospholipids (9).  Both AA and EPA serve 
as substrates for the cyclooxygenases (COXs), lipoxygenases (LOXs) and cytochrome 
P450 (CYPs) enzymes and their respective synthases that collaborate in the formation 
of a complex array of bioactive lipid metabolites.  Several metabolic products formed 
from AA, including prostaglandin E2 (PGE2), have been strongly associated with 
colorectal carcinogenesis (11).  However, minor structural differences between AA and 
EPA lead to the synthesis of a distinct array of lipid metabolites, a shift that may 
contribute to the tumor suppressive properties of the Ȧ-3 PUFAs (12).  
 
Since high-purity EPA-FFA is subject to rapid oxidation, a novel ionic derivative 
of EPA has been developed in the form of magnesium l-lysinate bis eicosapentaenoate 
(TP-252; Fig. 1A).  In the following study, we treated Apcǻ mice, an established 
mouse model of human FAP (13-15), with a diet containing increasing concentrations of 
the drug to assess the potential efficacy of TP-252 against intestinal tumor development.  
Here we show that treatment with TP-252 significantly suppresses intestinal tumor 
development in Apcǻ mice to a level comparable to that of EPA-FFA.  To gain further 
insight into the cancer protection afforded to the colon, we performed a comprehensive 
lipidomic analysis of fatty acid composition and eicosanoid metabolites.  Using the 
classification and regression tree (CART) method, these data suggest potential 
metabolic pathways associated with tumor protective mechanisms exerted by EPA.  The 
data presented here provide justification for further clinical investigation of TP-252 as 
novel treatment for FAP patients.  
Downloaded from https://academic.oup.com/carcin/advance-article-abstract/doi/10.1093/carcin/bgx136/4675322
by NERL, Daniel Rosenberg
on 07 December 2017
Ac
ce
pte
d M
an
us
cri
pt
 
 6 
 
Materials and methods  
 
TP-252  
 TP-252 has been formulated as a unique derivative of EPA-FFA, designed to 
deliver therapeutic levels of EPA-FFA to the intestinal mucosa.  The compound consists 
of magnesium L-lysinatebiseicosapentaenoate, an ionizable salt of eicosapentaenoic 
acid (EPA).  As shown in Figure 1A, TP-252 uses an amine̻ based scaffold that links 
magnesium di-L-lysinate to two molecules of the free fatty acid form of EPA (EPA-FFA).   
 
Animal treatment  
 Apcǻ mice were kindly provided by Dr. Christine Perret at the Universite' Paris 
(15) and maintained in the animal facility at UConn Health.  All mice were maintained in 
a light-cycled, temperature-controlled room and allowed free access to drinking water 
and diet ad libitum.  All animal experiments follow the institutional and national 
guidelines for the care and use of animals, and were conducted with approval from the 
Center for Comparative Medicine (CCM) at UConn Health.  Genotyping for Apc was 
performed using tail biopsies (15).  Male and female Apcǻ mice were included in each 
experimental group.  Mice were housed individually and fed two pellets of diet per day 
(~5g).  A modified AIN-93G diet with corn oil was used as a control.  All mice were 
randomized at 4 weeks of age and fed control diet for one week. The experimental 
groups of mice were switched to diets supplemented with 1, 2 and 4% TP-252, or 2.5% 
EPA-FFA (w/w; Research Diets, Inc.; Supplementary Table 1) at 5 weeks of age.  Each 
mouse had an average daily food intake of 2.5g.  Since TP-252 has a 65% EPA 
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 7 
payload, average mice (25 g) consume ~0.7, 1.3 and 2.6g/kg body weight (b.w.) of TP-
252 daily at 1, 2 and 4%, respectively.  Similarly, daily consumption of 2.5% EPA-FFA 
yields an intake of 2.5g/kg of b.w.  EPA-FFA diet was vacuum-packed for single use to 
avoid oxidative degradation of EPA.  Mice were weighed once a week throughout the 
entire study period. 
 
Tissue processing and analysis of tumor burden  
 Mice were sacrificed at 16 weeks of age, with the exception of two mice in the 
control group that were killed at 14 weeks of age.  At sacrifice, the small intestine and 
colon were immediately flushed thoroughly with ice-cold PBS and slit-open 
longitudinally.  Specimens were fixed flat in 10% neutral-buffered formalin and stored in 
70% ethanol.  Tissues were stained with 0.2% (v/v) methylene blue and the number and 
size of tumors (diameter) were scored under a dissecting microscope in a fully blinded 
manner.  Tumor load per mouse was determined by using the tumor diameter to 
calculate the spherical tumor volume (mm39 [ʌ[U3.  
 
Lipidomics Analysis 
Proximal full-thickness colon specimens were cut in half and snap-frozen in liquid 
nitrogen in a Precellys tube (Cayman Chemicals).  Global lipidomics analysis was 
performed at the Lipidomics Core at Wayne State University, as previously described 
(16).  Briefly, samples were prepared for LC-MS analysis using C18 cartridges.  HPLC 
was performed on a Prominence XR system (Shimadzu) using a Luna C18 column.  
HPLC eluate was directly introduced into the electrospray ionization source of a 
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 8 
QTRAP5500 mass analyzer (SCIEX) in the negative ionmode.  Multiple Reaction 
Monitoring (MRM) was used to detect unique molecular ion-daughter ion combinations 
for each of the 125 transitions to monitor a total of 169 lipid mediators (Supplementary 
Table 2).  Mass spectra for each detected lipid metabolite were recorded using the 
Enhanced Product Ion (EPI) feature to verify the identity of the detected peak.  Data 
were collected and quantified using Analyst 1.6.2 (SCIEX) and MultiQuant (SCIEX) 
software, respectively.  Correction for recovery efficiencies and relative quantitation of 
each analyte were performed using signals from each chromatogram corresponding to 
the spiked-in internal standards. Under standardized conditions of LC-MS quantitation, 
the detection limits for the eicosanoids are 1±2 pg on the column and the limit of 
quantitation is 5 pg at a signal-to-noise ratio of 3 (16). 
 
Classification & Regression Tree (CART) analyses 
We used the HPSPLIT procedure in SAS software (SAS Institute Inc., NC) to 
build a tree-based regression model to identify fatty acids that are the most important 
predictors of intestinal tumor numbers and colon tumor volume.  We pooled data from 
the control, 4% TP-252 and 2.5% EPA-FFA, and omitted fatty acids or eicosanoids that 
had more than 40% of the data below the limit of detection.  The rule generated at each 
step maximizes the class purity within each of the two resulting subsets.  For example, 
the splits in the tree are based upon the tissue levels of fatty acids (ng/mg of protein) or 
eicosanoids (pg/mg of protein) identified as 'best-predictors', and the tree shows the 
predicted mean number or volume of intestinal tumors based on those splits.  
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 9 
Statistical analyses 
For tumor and lipidomics analyses, GraphPad Prism V (GraphPad Software, Inc.) 
was used to perform statistical analyses.  Comparisons of mucosal fatty acid and 
eicosanoid levels and of small intestine and colon tumor number and size were made 
using one-way $129$ZLWK%RQIHUURQL¶Vpost-hoc test for pairwise comparisons.  For all 
statistical comparisons, a two-sided alpha level of significance of 0.05 was used.    
 
Results 
 
Treatment with TP-252 and EPA-FFA suppresses intestinal tumor development  
To compare the effects of TP-252 with the previously reported efficacy of EPA-
FFA on tumor development (9), Apcǻ mice were examined after 11-weeks of 
treatment with EPA-FFA or TP-252.  Mice treated with either EPA-FFA or TP-252 gained 
more body weight and showed a decrease in spleen weight, indicating reduced systemic 
inflammation associated with lessened disease severity (Table 1).  In the small intestine, 
treatment with TP-252 caused a significant, dose-related reduction in tumor number 
(1.2-, 1.7-, and 2.1-fold at 1, 2 and 4%, respectively) equivalent to EPA-FFA (1.8-fold; 
Table 1).  The protective effects of TP-252 were also evident in the incidence of tumors 
larger than 2-mm in diameter, which were significantly reduced with 2 and 4% TP-252 
and EPA-FFA (2.5-, 4.0- and 11.9-fold, respectively; Table 1).   
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In the colon, TP-252 and EPA-FFA treatment resulted in a trend towards reduced 
tumor numbers, although the differences did not reach statistical significance due to the 
relative infrequency of colon tumors (Table 1).  There was, however, a significant and 
dose-related reduction in colon tumor volume observed with 4% TP-252 (2.2-fold) and 
EPA-FFA (2.5-fold) compared to controls.  Moreover, the frequency of colon tumors 
larger than 3-mm was significantly reduced with 1% (1.3-fold) and 4% (1.4-fold) TP-252, 
which was comparable to the effect observed with EPA-FFA (1.6-fold; Table 1).  Most 
importantly, statistical analysis using a negative binominal model confirmed that the 
tumor protection observed with 4% TP-252 was as effective as that of EPA-FFA in both 
small intestine and colon (P=0.95).  
 
The ANOVA results showed there were statistically significant treatment-related 
differences in tumor multiplicity in the small intestine both for gender (P=0.04) and for 
treatment (P>0.0001), but not for the gender/treatment interaction (P=0.13), indicating 
that the treatment effect was consistent for both male and female mice.  For colon tumor 
multiplicity, there was a difference observed for gender (P=0.03), but not for treatment 
(P=0.23), and there was no suggestion of a gender/treatment interaction (P=0.79).  For 
colon tumor volume, there were no differences observed for gender (P=0.28); however 
the treatment effect was significant (P=0.01), and there was no suggestion of a 
gender/treatment interaction (P=0.79).  Importantly, the tumor protection observed with 
4% TP-252 suggested a similarity of effectiveness when compared to that of EPA-FFA 
(P=0.95).   
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TP-252 treatment alters mucosal fatty acid profiles  
Dietary supplementation with EPA has been shown to increase tissue levels of 
WKHȦ-IDWW\DFLGVZKLFKDUHVWUXFWXUDOO\GLVWLQFWIURPWKHȦ-6 fatty acids (Fig. 1B).  To 
determine the effects of EPA-FFA and TP-252 on fatty acid composition within the 
colonic mucosa, total fatty acid profiles in aliquots of proximal colon tissue were 
analyzed by LC-MS, as described under Materials and Methods.  As shown in Figure 
2A, the tissue levels of AA were significantly reduced by TP-252 in a dose-related 
manner (1.5-, 1.7- and 2.6-fold at 1, 2 and 4%, respectively), and also by EPA-FFA 
treatment (3.3-fold; Fig. 2A).  In addition, the levels of two AA metabolites, 
GRFRVDWHWUDHQRLFDFLG '7$DQGȦ-6 docosapentaenoic acid (DPA), were significantly 
reduced in each of the treatment groups (Fig. 2A).  As expected, EPA levels in the colon 
were markedly increased compared to controls in a dose-related manner (66-, 72- and 
136-fold at 1, 2 and 4% TP-252; respectively) and 88-fold with EPA-FFA (Fig. 2B).  
Although it was not statistically significant, incorporation of EPA was higher in the 4% 
TP-252 group compared to the EPA-FFA (P=0.07).  Furthermore, TP-252 significantly 
LQFUHDVHGWKHOHYHOVRIWKH(3$PHWDEROLWHVȦ-3 DPA (12-, 19- and 28-fold at 1, 2 and 
4% TP-252, respectively) and docosahexaenoic acid (DHA) (2.6-, 2.9- and 2.5-fold at 1, 
2 and 4% TP-252, respectively, Fig. 2B).  
  
To elucidate the effect of EPA treatment on the de novo synthesis of fatty acids 
(Fig. 1C), we compared the tissue levels of several non-essential fatty acids, including 
palmitic acid, palmitoleic acids, stearic acids and oleic acids.  As shown in 
Supplementary Figure S1, there were no significant treatment-related alterations to the 
levels of each of these non-essential fatty acids. 
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Eicosanoid profiles are significantly altered by changes to mucosal fatty acid 
composition 
AA and EPA are the primary sources of a diverse array of eicosanoid metabolites 
generated through a complex network of enzymatic and non-enzymatic oxidation 
reactions (17).  There are three major metabolic pathways that convert AA and EPA into 
their respective bioactive lipid metabolites (Fig. 1B).  We first compared the effects of 
EPA-FFA and TP-252 on the formation of the COX metabolites; AA-derived series-2 
prostanoids and EPA-derived series-3 prostanoids (Fig. 1B).   As shown in Figure 3A, 
the mucosal levels of PGE2 were reduced to a comparable extent by either 4% TP-252 
(2.1-fold) or EPA-FFA (2.3-fold).  In contrast, PGE3 levels were markedly increased by 
treatment with TP-252 (up to 80-fold at 4%) and EPA-FFA (93-fold).  Treatment with 
both TP-252 and EPA-FFA also affected the relative concentrations of the other COX-
derived metabolites, including prostaglandin F3Į3*)3ĮFig. 3B) and thromboxane B3 
(TXB3; Fig. 3C).  These levels were increased significantly relative to the corresponding 
levels of the AA-derived counterparts.  Although prostaglandin D2 (PGD2) levels were 
modestly reduced by drug treatment, there was no corresponding increase in PGD3 (Fig. 
3D).  Both forms of the J-series prostaglandins (PGJ2/PGJ3) were not significantly 
altered by EPA treatment (Fig. 3E).  
 
The LOX-dependent pathways generate series-4 and series-5 leukotrienes and 
hydroxy-eicosatetraenoic acids (HETEs) and hydroxy-eicosapentaenoic acids (HEPEs) 
from AA or EPA, respectively (Fig. 1B) (18).  As predicted from the observed tissue 
enrichment with EPA noted above (Fig. 2B), the levels of 12-HETE and 15-HETE were 
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significantly reduced, with the largest differences observed in the concentrations of 12-
HETE in mice fed 4% TP-252 and EPA-FFA (3.7- and 4.1-fold, respectively; Fig. 3F).  
Consistent with these reduced concentrations, tissue levels of a series of EPA-derived 
HEPEs were increased to a significant extent by drug treatment (Fig. 3F).  These 
changes were further reflected by an inverse relationship between LTB4 and LTB5, 
oxidized products of the 5/15-HETEs and 5/15-HEPEs, respectively (Fig. 3G).  
 
Finally, we measured the levels of lipid metabolites generated by the activities of 
the CYP epoxygenases, focusing on epoxy-eicosatrienoic acid (EpETrE) and epoxy-
eicosatetraenoic acid (EpETE), products of AA and EPA, respectively (17).  These 
epoxygenase products are rapidly hydrolyzed and converted into dihydroxy-
eicosatrienoic acid (DiHETrE) and dihydroxy-eicosatetraenoic acid (DiHETE).  Similar to 
the changes observed for the COX/LOX metabolites described above, the tissue levels 
of the AA-derived metabolites were generally reduced, whereas EPA-derived lipid 
products were increased (Fig. 3H & 3I).  Although 5,6-DiHETE has been identified as a 
ligand for the aryl hydrocarbon receptor (AhR) (19), which is an important signaling 
pathway for gastrointestinal homeostasis (20), its role in cancer has not been clearly 
defined. 
 
DHA metabolites are increased with EPA treatment 
DHA is a poor substrate for the COX enzymes and is primarily metabolized by 
the LOXs and CYPs, producing the hydroxy-docosahexaenoic acids (HDoHEs) (17).  As 
shown in Figure 4A, a wide-ranging panel of HDoHEs was increased in the proximal 
colon upon treatment with either TP-252 or EPA-FFA.  DHA and EPA can be further 
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metabolized via the LOXs to produce a series of resolvin Ds (RvD1-6) and resolvin Es 
(RvE1&3), respectively, which have potent immunomodulatory activities.  Although 
colonic mucosal levels of EPA were significantly increased by treatment with TP-252 and 
EPA-FFA (Fig. 2B), the tissue concentrations of most of the assayed resolvins were at 
or below the level of detection (data not shown), with the exception of RvD5.  As shown 
in Figure 4B, there was a moderate increase in RvD5 with 4% TP-252 and EPA-FFA.   
  
CART analyses predicts lipid metabolites associated with tumor protection 
To identify signature profiles of fatty acids, EPA treatment and tumor 
development, we built a tree-based regression model (CART) using data obtained from 
control, 4% TP-252 and EPA-FFA treated mice (n=53).  The average tissue levels of 
CART predicted fatty acids and eicosanoids for each group are summarized in 
Supplementary Table 3.  Here we show the results of these analyses for tumor 
multiplicity (small intestine) and tumor volume (colon).  The impact of EPA treatment on 
colon tumor multiplicity is also reported in Supplementary Figure S2. 
 
As shown in Figure 5A, the average tumor number in the small intestine was 42 
in Node 0.  The first split predicted that 68% of mice (36/53) had tissue levels of EPA 
higher than 52.9 ng/mg, which was correlated with lower tumor number (Node 2; avg. = 
31).  This node consisted of the EPA-treatment groups, highlighting the protection 
afforded by EPA.  Node 2 was further subdivided into myristic acid and dihomo-g-
linolenic acid (DGLA), indicating an average tumor multiplicity of 19 (Node 7; Fig. 5A).  
Each of the mice in the control group were associated with lower levels of EPA, with an 
average of 64 tumors (Node 1).  This node was further bifurcated by cerotic acid, in 
Downloaded from https://academic.oup.com/carcin/advance-article-abstract/doi/10.1093/carcin/bgx136/4675322
by NERL, Daniel Rosenberg
on 07 December 2017
Ac
ce
pte
d M
an
us
cri
pt
 
 15 
which mice were separated equally between higher (Node 3) and lower (Node 4) tumor 
multiplicity (avg. = 43 vs. 88; Fig. 5A). 
 
Interestingly, the regression tree analysis produced a distinct lipid profile for 
colon tumor volume.  As shown in Figure 5B, the first separation predicted that 87% of 
mice (46/53) with DHA levels exceeding 101.9 ng/mg had smaller tumors (avg. = 13 
mm3; Node 2), while the remaining 13% of mice had approximately three times larger 
tumors (Node 1).  Since the average level of DHA is between 135.3 to 342.0 ng/mg 
across the three groups (Supplementary Table 3), a DHA cut-point above 101.9 ng/mg 
may be sufficient for cancer protection.  The majority of EPA-treated mice segregated 
towards smaller colon tumors together with higher levels of DHA (Fig. 5B).  
Furthermore, suppression of colon tumor growth was associated with lower levels of 
erucic acid (Node 5; Fig. 5B).  However, some additional benefit was correlated with 
palmitoleic acid and heptadecenoic acid (Node 8, 9; Fig. 5B).  The majority of mice with 
DHA <101.9 ng/mg were found in the control group (Node 1).  Further bifurcation 
generated two nodes based upon the levels of linoleic acid (LA), in which 57% of mice 
(4/7) had lower LA and smaller tumor size (Node 3; avg. = 17 mm3).  
 
 As shown in Figure 5C and 5D, CART analysis was utilized to stratify fatty acid- 
derived eicosanoid metabolites for their effects on tumorigenesis.  For both small 
intestine and colon, there was a strong correlation between 14-HDoHE and tumor 
protection.  The majority of mice had higher levels of 14-HDoHE, which were associated 
with both lower tumor multiplicity in small intestine and colon tumor volume (avg. = 32 
and 11 mm3, respectively) (Node 2; Fig. 5C & 5D).  Similar to the results obtained with 
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fatty acid analysis, most EPA-treated mice had smaller tumors (number and volume) at 
the first separation.  In further splits, tissue levels of 8-isoPGF2ĮE3*)2Įfollowed by 
19,20-DiHDoPE were associated with lower tumor multiplicity in the small intestine 
(Node A; avg. = 20; Fig. 5C).  Higher levels of PGE3 correlated with tumor protection in 
the small intestine  (Node 8; avg. = 28).  Interestingly, treatment with TP-252 or EPA-
FFA failed to suppress tumor development if PGE3 levels were below a critical level 
(Node 7; avg. = 53).  Control mice with lower levels of 14-HDoHE (Node 1) were 
separated by the levels of 13,14dh-15k-PGE1 (Node 4), a breakdown product of PGE1.  
As shown in Figure 5D, in addition to 14-HDoHE, suppression of colon tumor growth 
was strongly associated with 13-HODE (Node 5) and PGJ2, with an average tumor 
volume of 2 mm3 (Node 7; Fig. 5D).  These particular nodes were comprised almost 
entirely of EPA-treated mice.  The group with more PGJ2 (Node 8) was further split by 
PGF2Į, with colon tumor volume reduced to an average of 7 mm3 (Node A; Fig. 5D).   
 
Finally, mice with less 14-HDoHE (Node 1) were further separated by the levels 
of resolvin D5 (RvD5), with an average colon tumor volume of 72 mm3 (Node 3) and 27 
mm3 (Node 4) (Fig. 5D).  RvD5 is a DHA-derived specialized pro-resolving lipid mediator 
(SPM) with potent anti-inflammatory activity (21).  Although the tissue levels of RvD5 
(Fig. 4B) were not correlated with DHA (Fig. 2B), RvD5 was one of the strongest 
predictors of colon tumor size.  The RvD5 cut-point (23.3 pg/mg) was much lower than 
the average levels of RvD5, ranging from 524.2 to 754.5 pg/mg (Supplementary Table 
3), suggesting that even relatively small amounts of RvD5 may significantly contribute to 
tumor protection.  
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Discussion 
 
TP-252, magnesium L-lysinate bis eicosapentaenoate, is a novel molecular entity 
that delivers beneficial levels of EPA-FFA to tissues and can be developed for the 
treatment of FAP.  The present study extends earlier findings in ApcMin/+ (9) and 
demonstrates that treatment with TP-252 significantly suppresses intestinal tumor 
development in a second Apc cancer model, Apcǻ mice.  As reviewed in-depth by 
Cockbain et al. (22), Z-3 PUFAs such as EPA elicit a wide array of anti-tumor activities, 
demonstrated in cell culture systems and in pre-clinical tumor models, as well as in 
human clinical trials.  Although the precise mechanisms by which EPA suppresses tumor 
growth are not entirely understood, a unifying principle for its protective effects is largely 
attributed to its ability to act as a competitive inhibitor of AA, exerting its effects across a 
wide range of metabolic pathways.  Our study uncovers a wide range of metabolic 
changes provoked by EPA that we believe may directly contribute to its tumor-
suppressive properties.  
 
 Both AA and EPA are essential fatty acids that must be obtained from dietary 
sources.  These fatty acids provide substrates to more than 20 individual receptor-
mediated signaling cascades; however, subtle differences in the chemical structures of 
AA and EPA underscore their disparate cellular actions (22, 23).  AA, which is derived 
largely from LA, is a 20-FDUERQȦ-6 fatty acid with four double bonds (C20:4).  On the 
other hand, EPA, which is ingested from fish oils or indirectly derived IURP Į-linolenic 
acid (ALA), is a 20-FDUERQ Ȧ-3 fatty acid with five carbon double bonds (C20:5).  An 
extra double bond in EPA results in the production of distinct set of metabolites, which 
may elicit anti-inflammatory properties.  One key metabolic process that distinguishes 
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the biological actions of EPA from AA is its efficient conversion to DHA, a 22-FDUERQȦ-3 
fatty acid with six double bonds (C22:6), which gives rise to a wide range of bioactive 
lipid metabolites.  Included among the DHA metabolites are the maresins and protectins, 
SPMs that play an important role in the resolution of inflammation (24).  The role of 
these particular SPMs in intestinal carcinogenesis is presently unknown, but our data 
suggest potential contributions to the protection afforded by EPA. 
 
Our study establishes that TP-252 is effective at delivering high concentrations of 
EPA into the colonic mucosa.  Resulting concentrations are sufficient to markedly alter 
tissue fatty acid composition, causing a subsequent shift in the overall profile of 
downstream lipid metabolites.  Using a CART analyses, we identified distinct lipid 
signatures that were associated with cancer protection.  At the outset, tissue levels of 
EPA were strongly correlated with tumor multiplicity in the small intestine, providing an 
internal validation of our dietary protocol.  In the colon, CART analysis identified DHA as 
the strongest predictor of tumor protection.  The beneficial effects of DHA have been 
demonstrated earlier in several Apc-mutant mouse models (26, 27).  However, the 
administration of EPA alone or as a fish oil preparation providing both EPA and DHA, 
indicated improved tumor protection (9, 26).  The  beneficial effects afforded by EPA, 
compared to DHA alone, may depend upon the model system employed.  In the case of 
Apc-mutant mice, activation of the COX-2/PGE2 axis is important in tumor growth that 
displacing AA with EPA, the direct source of prostaglandins, would be expected to exert 
a beneficial effect (13, 14, 28).  While DHA is a structurally poor substrate for COXs, 
EPA can produce, for example, PGE3 that can counteract the pro-tumorigenic effects of 
PGE2.  Therefore, EPA serves as a universal lipid precursor that provides substrate for a 
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diverse array of lipid metabolites, many of which may ultimately contribute to its anti-
cancer activities.  
 
DHA is formed by the actions of the elongases and delta-6 desaturases, followed 
by ȕ-oxidation.  These lipid-modifying enzymes play an important role in energy 
generation, particularly during cancer development (29).  In fact, dysregulated lipid 
metabolism has been shown in a variety of cancers to directly influence tumor initiation 
and growth (30, 31).  For example, melanomas, lung cancers (32) and breast cancers 
(33) have increased activity of the delta-6 desaturase that controls the in situ formation 
of AA directly within the tissue, thereby promoting cell proliferation and survival via 
elevated prostaglandin synthesis.  Moreover, the selective inhibition of the delta-6 
desaturase by SC-26196 reduces the number of intestinal tumors in ApcMin/+ mice by 
37% (34).  In the present study, there is evidence for enhanced lipid metabolism 
influencing tumor development, demonstrated by the association between higher levels 
of cerotic acid and increased tumor multiplicity in the small intestine (Fig. 5A).  Cerotic 
acid belongs to a family of very long chain saturated fatty acids (VLCFA, C26:0), and is a 
minor fatty acid component of human tissues (35).  Increased serum levels of this fatty 
acid are often associated with coronary risk factors, such as metabolic syndrome, 
atherosclerosis and systemic inflammation (36).  In fact, cerotic acid levels have recently 
been proposed as a metabolic serum marker for CRC, together with up-regulation of the 
elongases, ELOVL1 and ELOVL6, within colon tumor tissues (37).  In the present study, 
an involvment of cerotic acid was exclusively found within mice fed the control diet, 
suggesting that the fatty acid may be a lipid signature unique in the tumor-bearing 
Apcǻ mice.  Although the biological activity of cerotic acid towards colon 
carcinogenesis has not yet been defined, it is possible that EPA may exert control over 
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the synthesis and/or function of this fatty acid.  For example, if we assume that 
dysregulated lipid metabolism is present in tumor-bearing mice, excess levels of EPA 
may facilitate the formation of DHA, which in turn produces metabolites that can shift 
early neoplastic growth towards a growth suppressive phenotype.  In fact, eicosanoid 
metabolites most strongly associated with tumor protection were 14-HDoHE and 19, 20-
DiHDoPE, DHA-derived metabolites formed by the actions of the LOX and CYP, 
respectively (Fig. 5C & 5D).  Freeman et al. (38) recently showed that 14-HDoHE is a 
substrate for 15-PGDH, generating the electrophilic metabolite, 14-oxoDHA, which has 
been shown to inhibit LPS-induced pro-inflammatory cytokine expression in primary 
alveoloar macrophages.  Moreover, DHA is metabolized by macrophage-derived 12-
LOX to form 14-HDoHE, leading to the formation of maresins, a member of the SPM 
class of lipids (39, 40).  SPMs elicit their effects in part by blocking neutrophil migration, 
while enhancing macrophage phagocytosis of apoptotic neutrophils, thus limiting 
neutrophil-mediated tissue damage (41).  Several isomers of the hydroxy-DHA 
metabolites been reported to have bioactivity against tumor growth.  For example, 4-
HDoHE (4-HDHA) was shown to directly inhibit endothelial cell proliferation and 
angiogenesis via peroxisome proliferator-DFWLYDWHGUHFHSWRUȖ33$5ȖHIIHFWVWKDWDUH
independent of its immunomodulatory activity (42).  Moreover, as  shown by O'Flaherty 
et al. (42), treatment of prostate cancer cells with the 17-series DHA metabolites, 
including 17-HDoHE (17-HDHA), significantly reduced cell proliferative activity.  Although 
a wide range of anti-inflammatory activities for 14-HDoHE, 19,20-DiHDoPE and their 
direct metabolites have been established, the potential role of these bioactive lipid 
metabolites on colon carcinogenesis are presently unknown.  To our knowledge, this is 
the first study to report the potential impact of these LOX and CYP metabolites on 
intestinal tumor development.  
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The influence on carcinogenesis of a number of metabolic products derived from 
AA via the COXs have been studied extensively (reviewed in (43)).  In particular, our 
laboratory has validated a direct role for inducible PGE2 in the initiation and promotion of 
intestinal cancer using a mouse genetic knockout model of mPGES-1 (13, 14, 28).  In 
the present study, CART analysis identified EPA-derived PGE3 as one of the strongest 
predictors of tumor protection in small intestine.  Emerging evidence suggests that the 
antagonistic effects of EPA on AA metabolism are due in part to their relative catalytic 
efficiency towards the COX/LOX/CYP enzymes and the binding affinities of the 
respective eicosanoid products for their cognate receptors (17, 44).  For example, the 
relative activity of the COX enzymes towards EPA is only 10-30% of its activity towards 
AA (45).  Furthermore, the downstream synth ses, mPGES-1 and PGD synthase 
(PGDS), have three-fold less efficiency for generating PGE3 and PGD3 when EPA is the 
available substrate (45).  Moreover, Wada et al. (45) demonstrated that PGE3 is 
approximately 2- to 3-fold less effective than PGE2 in binding efficiency to the EP1-3 
receptors within the cell membrane fraction of human kidney cells (HEKs).  Similarly, 
LTB4, an AA-derived leukotriene that is a potent activator of neutrophils and eosinophils, 
is at least five times more active than its EPA counterpart, LTB5 (46).  Directly related to 
this observation, we found an increase in the levels of LTB5 upoin treatment with either 
TP-252 or EPA-FFA, an effect that could potentially influence immune cell activation.  
Such an effect would likely contribute to the observed reduction in systemic inflammation 
found in the EPA-fed mice (Table 1).  Taken together, our findings suggest that EPA-
derived metabolites can markedly interfere with the formation of downstream AA-derived 
lipid mediators and simultaneously de-accelerate the rate of receptor-mediated activity 
that is dependent upon these eicosanoids.  However, we cannot exclude the possibility 
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that many of the EPA-derived metabolites that were increased following EPA treatment 
may also independently contribute to its tumor suppressive properties.      
 
In the present study, we selected the proximal colon for our lipidomic analysis 
because ApcǼ14/+ mice do not typically develop tumors within this region of the intestine, 
thus circumventing the potential variability of these experimental endpoints associated 
with the presence of tumors.  Thus we have provided a broad-based pe spective of the 
metabolic changes associated with long-term EPA treatment to normal colonic mucosa 
in close proximity to Apc-initiated tumors.  Recently, Djuric et al. (25) performed a 
lipidomic analysis of normal colonic mucosa and tumor tissue isolated from carcinogen-
treated rats maintained on either a Western diet or a diet enriched in fish oils.  
Interestingly, the diets caused differential changes to fatty acid composition of the 
normal mucosa compared to tumor tissue.  In the tumors, there was a distinct lipogenic 
phenotype that was absent in normal mucosa (25).  Based upon these recent findings, 
future experiments may be warranted to investigate the effects of TP-252 on lipid 
metabolism directly within Apc-mutant tumors, data that would provide additional insight 
into the tumor protection associated with EPA treatment.  
 
In summary, we have demonstrated the chemopreventive efficacy of a novel 
EPA derivative, TP-252, on intestinal tumor development in Apc¨14/+ mice.  The 
protection afforded by TP-252 is comparable to that of EPA-FFA, the free fatty acid form 
of EPA that has been shown earlier in both clinical (7) and pre-clinical (9) studies to have 
therapeutic efficacy in FAP disease.  Our comprehensive lipidomics analysis shows that 
treatment with TP-252 can simultaneously enhance both the incorporation of EPA into 
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colonic tissue, thereby displacing AA, while causing a pronounced metabolic redirection 
of fatty acids towards EPA-derived, anti-inflammatory lipid metabolites.  Furthermore, the 
application of CART analyses to the global lipidomic data provide new insights into 
specific eicosanoid metabolites and their potential to exert control over early neoplasia.  
Based upon these promising pre-clinical findings, further studies are warranted to 
elucidate the exact mechanisms by which long-term treatment with this Ȧ-3 fatty acid 
derivative may elicit its tumor protection, particularly in high-risk FAP patients.   
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Figure Legends 
 
Figure 1:  Structure of TP-252 and fatty acid metabolizing pathways.  (A) Structure 
of TP-252 showing an amine̻ based scaffold that links magnesium di-L-lysinate to the 
free fatty acid form of EPA (EPA-FFA). (B) Essential fatty acid synthesis pathways 
showing Ȧ-6 and Ȧ-3 series.  A panel of eicosanoid metabolites synthesized via 
respective enzymes are also depicted.  (C) Non-essential fatty acids synthesis pathways 
showing Ȧ-7, Ȧ-9 series and saturated fatty acid (SFA).  Number of carbons and double 
bonds are denoted for each fatty acid.  A panel of fatty acids is synthesized by a series 
of desaturation and elongation reactions.  The respective enzymes that are responsible 
for generating lipid metabolites are depicted.  ǻ-6-d, delta-6-GHVDWXUDVHǻ-9-d; delta-9-
desaturase; ELOVL, elongase. 
 
Figure 2: Changes in mucosal fatty acid profiles by dietary supplementation with 
TP-252 and EPA-FFA.  A comprehensive lipidomic analysis of the proximal colon was 
performed as described under Materials and Methods.  The data show alterations to the 
levels of AA and its fatty acid metabolites, DTA and Ȧ-6 DPA (A), EPA and its fatty acid 
metabolites (B). Bars indicate means ± S.E.M.  Asterisks indicate statistically significant 
differences in treatment groups relative to control; *=P<0.05, **=P<0.01, ***=P<0.001. 
 
Figure 3: Changes in COX-, LOX- and CYP-generated eicosanoid metabolites by 
dietary supplementation with TP-252 and EPA-FFA.  Colonic tissue levels of AA-
derived eicosanoids and their EPA-derived counterparts show an inverse relationship 
with increasing concentrations of TP-252.  Tissue levels of PGE2 and PGE3 (A), PGF2Į
and PGF3ĮB), TXB2 and TXB3 (C), PGD2 and PGD3 (D), 15d-PGJ2 and 15d-PGJ3 (E), 
HETEs and HEPEs (F) LTB4 and LTB5 (G), AA-derived DiHETrEs (H) and EPA-derived 
5,6-DiHETE (I).  Bars indicate means ± S.E.M.  Asterisks indicate statistically significant 
differences in treatment groups relative to control; *=P<0.05, **=P<0.01, ***=P<0.001. 
 
Figure 4:  DHA metabolites are increased by treatment with TP-252 or EPA-FFA.  
EPA treatment increases DHA metabolites. Tissue levels of DHA-derived metabolites 
(HDoHEs) (A) and RvD5 (B).  Bars indicate means ± S.E.M.  Asterisks indicate 
statistically significant differences in treatment groups relative to control; *=P<0.05, 
**=P<0.01, ***=P<0.001. 
 
Figure 5:  CART analyses identify distinct lipid metabolite profiles associated with 
tumor protection.  Regression tree analysis predicts a set of fatty acids or eicosanoids 
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that are strongly correlated with the number or size of intestinal tumors.  The splits in the 
trees are based upon the tissue levels of fatty acids (ng/mg of protein) or eicosanoids 
(pg/mg of protein) indicated above the nodes.  Fatty acids associated with tumor 
multiplicity in the small intestine (A) and tumor size in the colon (B).  Eicosanoids 
associated with tumor multiplicity in the small intestine (C) and tumor size in the colon 
(D).  The relative thickness of the tree branch indicated in the diagram approximates the 
number of mice that are split into their respective nodes.  N, number of animals; Avg, 
average number or size (mm3) of tumors; Ctl, number of mice in the control group; TP, 
number of mice in the TP-252 treated group; EPA, number of mice in the EPA-FFA-
treated group.   
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Supplementary Figure S1:  Treatment with TP-252 and EPA-FFA does not modify 
the levels of fatty acids generated by de novo synthesis.  A comprehensive lipidomic 
analysis of the proximal colon was performed as described under Materials and 
Methods.  Tissue levels of palmitic acid, palmitoleic acid, stearic acid and oleic acids in 
each of the treatment group are shown.  Bars indicate means ± S.E.M.   
 
Supplementary Figure S2:  CART analyses identify distinct lipid metabolite 
profiles associated with colon tumor numbers.  Regression tree analyses predict a 
set of fatty acids or eicosanoids that are strongly correlated with the number of tumors in 
the colon.  Fatty acids (A) and eicosanoids (B) associated with tumor multiplicity.  N, 
number of animals; Avg, average number or size (mm3) of tumors; Ctl, number of mice in 
control group; TP, number of mice in TP-252 treated group; EPA, number of mice in 
EPA-FFA treated group.  The tissue levels of fatty acids (ng/mg of protein) or 
eicosanoids (pg/mg of protein) are indicated above the nodes.  
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